1. Home
  2. IMTE vs GRI Comparison

IMTE vs GRI Comparison

Compare IMTE & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integrated Media Technology Limited

IMTE

Integrated Media Technology Limited

HOLD

Current Price

$0.96

Market Cap

2.3M

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$0.21

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMTE
GRI
Founded
2008
2018
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3M
1.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IMTE
GRI
Price
$0.96
$0.21
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.00
AVG Volume (30 Days)
1.7M
5.0M
Earning Date
09-26-2025
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$123,337.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.75
N/A
52 Week Low
$0.50
$0.18
52 Week High
$3.17
$11.90

Technical Indicators

Market Signals
Indicator
IMTE
GRI
Relative Strength Index (RSI) 70.28 26.67
Support Level $0.53 $0.18
Resistance Level $1.07 $0.25
Average True Range (ATR) 0.12 0.04
MACD 0.05 0.05
Stochastic Oscillator 77.37 16.99

Price Performance

Historical Comparison
IMTE
GRI

About IMTE Integrated Media Technology Limited

Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: